Author

Melissa Miceli

Observed names: M Miceli, M. Miceli, MELISSA MICELLI

Institution: United Therapeutics (United States)

Observed institution: United Therapeutics (United States)

OpenAlex ID: A5017458730

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

2022 · Leslie A. Spikes, Abubakr A. Bajwa, et al. · Pulmonary Circulation · 40

Plain Language Summary of the INCREASE Study: Inhaled Treprostinil (Tyvaso) for the Treatment of Pulmonary Hypertension Due to Interstitial Lung Disease

2023 · Natalie West, Karen Smoot, et al. · Future Cardiology · 4

Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: event-free survival in INCREASE study open-label extension

2022 · S Nathan, R Argula, et al. · 13.01 - Pulmonary hypertension · 4

Comparison of Pharmacokinetics of 3 Doses of Treprostinil Inhalation Powder (Tyvaso DPI) and 3 Doses of Tyvaso in Healthy Normal Volunteers

2022 · K. El-Kersh, R. Restrepo Jaramillo, et al. · 1

Breeze: Clinical Outcomes and Pharmacokinetics of Treprostinil Inhalation Powder (tyvaso Dpi)

2021 · SHELLEY SHAPIRO, LESLIE SPIKES, et al. · CHEST Journal · 1

Works count: 5

Citation count: 50

H-index: 3

I10-index: 1